Published in Vaccine Weekly, December 10th, 2003
Total revenues for the third quarter of 2003 were $4.3 million compared to third-quarter 2002 revenues of $2.3 million.
Revenues for the third quarter included $3.6 million of product sales compared to $1.8 million of product sales in the prior-year period, a 100% increase.
Product sales increased across all of the company's product lines. In particular, sales benefited from the introduction of the company's two new prenatal vitamin products, as well as increased orders for AVC Cream, Nestabs, and Gynodiol. Revenue from research and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.